Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Trogarzo | ibalizumab-uiyk | Theratechnologies | N-761065 RX | 2018-03-06 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
trogarzo | Biologic Licensing Application | 2024-12-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hiv infections | EFO_0000764 | D015658 | B20 |
Expiration | Code | ||
---|---|---|---|
ibalizumab, Trogarzo, Theratechnologies Inc. | |||
2025-03-06 | Orphan excl. |
Code | Description |
---|---|
J1746 | Injection, ibalizumab-uiyk, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
Viral drug resistance | D024882 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Ibalizumab |
INN | ibalizumab |
Description | Ibalizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >3O2D:H|ibalizumab heavy chain
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAY
MELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG
>3O2D:L|ibalizumab light chain
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLT
ISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 3O2D, 7T0R |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1743029 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12698 |
UNII ID | LT369U66CE (ChemIDplus, GSRS) |